Stock 300683 WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Company Wuhan Hiteck Biological Pharma Co.,Ltd

Equities

300683

CNE1000034C5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 02/07/2024 am IST 		5-day change 1st Jan Change
21.74 CNY +1.16% Intraday chart for Wuhan Hiteck Biological Pharma Co.,Ltd +3.57% -39.80%
21/04 Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
20/02 Wuhan Hiteck Biological Pharma Co.,Ltd completed the acquisition of a 6.995% stake in Beijing Shadong Biotechnology Co., Ltd. from JunHe Enterprise Management Co., Ltd., Yang Shifang, Cui Junsheng, Sha Bingdong and Guo Cheng CI

Business Summary

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segment’s businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.

Number of employees: 1,520

Sales per Business

CNY in Million2022Weight2023Weight Delta
Pharmaceutical Technical Services
64.9 %
319 46.8 % 391 64.9 % +22.32%
Biopharmaceutical
26.2 %
159 23.2 % 158 26.2 % -0.59%
Pharmaceutical Intermediate Production and Sales
8.1 %
201 29.4 % 49 8.1 % -75.69%
In Vitro Diagnostics Reagent
0.8 %
4 0.6 % 5 0.8 % +20.69%
Other
0.1 %
0 0.0 % 0 0.1 % +354.39%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
100.0 %
684 99.4 % 602 100.0 % -12.02%
Foreign
0.0 %
4 0.6 % 0 0.0 % -98.58%

Managers

Managers TitleAgeSince
Ya Chen CEO
 Chief Executive Officer 52 17/04/17
Huang Chen CHM
 Chairman 49 01/00/01
Han Zhen Xia DFI
 Director of Finance/CFO 61 01/00/01
Jing Du BRD
 Director/Board Member 40 01/03/01
Hua Dong Tang BRD
 Director/Board Member 46 01/02/01
Kun Yang IRC
 Investor Relations Contact - -
Sheng Qiang Li PRN
 Corporate Officer/Principal 48 01/00/01

Members of the board

Members of the board TitleAgeSince
Han Zhen Xia DFI
 Director of Finance/CFO 61 01/00/01
Sheng Qiang Li PRN
 Corporate Officer/Principal 48 01/00/01
Ya Chen CEO
 Chief Executive Officer 52 17/04/17
Jia Feng Zhu BRD
 Director/Board Member 55 28/15/28
Hua Dong Tang BRD
 Director/Board Member 46 01/02/01
Ming Dong Ran BRD
 Director/Board Member 49 22/21/22
Jie Yan BRD
 Director/Board Member 59 12/18/12
Jing Du BRD
 Director/Board Member 40 01/03/01
Man Qi Zhao CHM
 Chairman 50 16/23/16
Hai Bing Zhou BRD
 Director/Board Member 54 16/23/16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 130,894,391 61,107,956 ( 46.68 %) 0 46.68 %

Shareholders

NameEquities%Valuation
Xiang Long Shen
2.282 %
2,781,668 2.282 % 9 M ¥
Nuode Asset Management Co., Ltd.
2.166 %
2,640,047 2.166 % 9 M ¥
Caitong Fund Management Co., Ltd.
1.254 %
1,528,311 1.254 % 5 M ¥
UBS Asset Management Switzerland AG
0.6845 %
834,326 0.6845 % 3 M ¥
Eagle Investment Holdings Co. Ltd. /Private Equity/
0.5405 %
658,820 0.5405 % 2 M ¥
Bosera Asset Management Co., Ltd.
0.0547 %
66,682 0.0547 % 221 660 ¥
HFT Investment Management Co., Ltd.
0.009025 %
11,000 0.009025 % 36 565 ¥
China Merchants Fund Management Co., Ltd.
0.003774 %
4,600 0.003774 % 15 291 ¥
Guotai Asset Management Co., Ltd.
0.000492 %
600 0.000492 % 1 994 ¥
NameEquities%Valuation
Ya Chen
71.59 %
6,450,000 71.59 % 21 M ¥

Company contact information

Wuhan Hiteck Biological Pharma Co., Ltd.

Hiteck Science & Technology Park Economic & Technological Dev Zone

430056, Wuhan

+

http://www.hiteck.com.cn
address Wuhan Hiteck Biological Pharma Co.,Ltd(300683)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD Stock Wuhan Hiteck Biological Pharma Co.,Ltd
-39.80% 391M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 816B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.31% 634B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 323B
ABBVIE INC. Stock AbbVie Inc.
+7.09% 293B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 238B
ROCHE HOLDING AG Stock Roche Holding AG
+1.64% 222B
NOVARTIS AG Stock Novartis AG
+13.66% 218B
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300683 Stock
  4. Company Wuhan Hiteck Biological Pharma Co.,Ltd